Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 17 items

Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials

Beutler, A. S. , Kulkarni, A. , Kanwar, R. , Qin, R. ... - AACR - AACR 2013 Annual Meeting - 2013

Abstract - Secondary-not-in-original - Primary - Symptom Inter - N08C1 , N08CA

Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML)

Eisfeld, Ann-Kathrin , Marcucci, G. , Liyanarachchi, S. , Döhner, K. ... - AACR - AACR Annual Meeting - 2012

Abstract - Secondary - Primary - Leuk Corr Sci - C9665

Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%

Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012

Abstract - Primary - Primary - Breast - ACOSOG-Z1031B

Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance)

Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - Cancer Res - 2019

Abstract - Secondary - Primary - GI - CALGB-80405

A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803

Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012

Abstract - Secondary - Primary - GI - CALGB-89803

Genetic prediction of VEGF-A plasma levels in cancer patients CALGB 80303 (Alliance)

Innocenti, Federico , Jiang, Chen , Sibley, Alexander ... - AACR - Cancer Res - 2016

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-80303

ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC (Alliance)

Johnson, Radia M. , Qu, Xueping , Thomas, Joshua , Kschonsak, Yvonne ... - AACR - Cancer Res - 2020

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib

Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res. - 2012

Abstract - Secondary-not-in-original - Primary - GI - N054C

Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy

Lafky, J. , Bot, B. , Morlan, B. ... - AACR - Proc Am Assoc Can Res - 2011

Abstract - Secondary-not-in-original - Primary - GI - N054C

PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res. - 2012

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-9741

High ERG expression levels predict adverse outcome and refine molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study

Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Vukosavljevic, T. ... - AACR - AACR Annual Meeting - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012

Abstract - Primary - Preliminary - Breast - N0937

FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients

Neviani, P. , Santhanam, R. , Oaks, J. , Eiring, A. , Notari, M. ... - AACR - AACR Annual Meeting - 2007

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9665

A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Patel, Jai N. , Jiang, Chen , Owzar, Kouros , Hertz, Daniel L. ... - AACR - Cancer Res. - 2016

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-90401

Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study

Perez, E. , Eckel-Passow, J. , Ballman, K. , Anderson, S. ... - AACR - Cancer Res. - 2012

Abstract - Secondary-not-in-original - Primary - Breast - N9831

Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study

Schwind, S. , Marcucci, G. , Holland, K. B. , Mrózek, K. ... - AACR - AACR Annual Meeting - 2010

Abstract - Secondary - Primary - Leuk Corr Sci - C20502 , C9665 , C8461 , C9621 , C19808

A randomized phase II trial of vitamin D vs placebo in premenopausal women: CALGB 70806

Wood, M. E. , Kinglsey, F. , Ambaye, A. B. , Yee, L. , Jung, S. J. ... - AACR - Cancer Res. - 2011

Abstract - No-Endpoint - Trial-Description-Only - Prevention - CALGB-70806